890808P

Avanti

22:0 Trehalose

D-(+)-trehalose 6,6′-dibehenate, powder

Empirical Formula (Hill Notation):
C56H106O13
CAS号:
分子量:
987.43
NACRES:
NA.25
价格与库存信息目前不能提供

form

powder

packaging

pkg of 1 × 25 mg (890808P-25mg)
pkg of 1 × 5 mg (890808P-5mg)

mfr. no.

Avanti Polar Lipids, 890808P

shipped in

dry ice

storage temp.

−20°C

SMILES string

O[C@H]([C@@H](COC(CCCCCCCCCCCCCCCCCCCCC)=O)O[C@H](O[C@@H](O[C@@H]([C@H]([C@@H]1O)O)COC(CCCCCCCCCCCCCCCCCCCCC)=O)[C@@H]1O)[C@@H]2O)[C@@H]2O

General description

22:0 Trehalose is a bioactive glycolipid and an analog of mycobacterial cord factor.

Application

22:0 Trehalose has been used as an adjuvant for Chlamydia vaccine. It has also been used as a component in adjuvant DMT (dimethyldioctadecylammonium/monophosphoryl lipid A/trehalose 6,6′-dibehenate (DDA/MPL/TDB)) to prepare DMT liposome adjuvanted CTT3H (polyprotein) vaccine.

Biochem/physiol Actions

Incorporation of trehalose 6,6′-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets. It acts as an immunomodulator. 22:0 Trehalose is considered less toxic and an efficient vaccine adjuvant for tuberculosis.

Packaging

5 mL Amber Glass Screw Cap Vial (890808P-25mg)
5 mL Amber Glass Screw Cap Vial (890808P-5mg)

Other Notes

For R&D use only. Not for drug, household, or other uses.

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because...
Xindong Teng et al.
Human vaccines & immunotherapeutics, 11(6), 1456-1464 (2015-04-24)
Different strategies have been proposed for the development of protein subunit vaccine candidates for tuberculosis (TB), which shows better safety than other types of candidates and the currently used Bacillus Calmette-Guérin (BCG) vaccine. In order to develop more effective protein...

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。